TRPV1 Antibody - #DF10320

Fig. 5 TRPV1 in GABAergic neurons of the vlPAG in CPA mice. Expression of TRPV1 in the pinch pain CPA model (a) and morphine withdrawal CPA model (b). (two sample t test, n = 6). p-TRPV1 was upregulated in the pinch pain CPA model (c, d) and morphine withdrawal CPA model (e, f) [immunofluorescence image (c, e), scale bar, 50 μm (n = 3); western blotting (d, f), ***P 

FIGURE 8 Bufalin-PLGA MS suppressed the protein expression of TRPV1 and P2X7 in CCI rats. (A) SDS-PAGE bands of TRPV1 and P2X7 protein in the DRG of different group rats. (B) Expression levels of TRPV1 protein in the DRG of different group rats. (C) Expression level of P2X7 protein in the DRG of different group rats. Data are expressed in the form of mean ± SEM, n = 3. ###p < 0.001 compared to the control group, *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the CCI group.

FIGURE 9 Expressions of TRPV1 and P2X7 were visualized and quantified via immunofluorescence staining. (A) Immunofluorescence detection of TRPV1 protein in the DRG; green and blue staining represent TRPV1 and DAPI, respectively. (B) Immunofluorescence detection of P2X7 protein in the DRG; green and blue staining represent P2X7 and DAPI, respectively. Data is expressed in the form of mean ± SEM, n = 3. ###p < 0.001 compared to the control group, *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the CCI group. (Scale bar = 20 µm).

Figure 5. Capsaicin (CAP) synergizes with Cisplatin (DDP) induced mitochondrial apoptosis in Tongue squamous cell carcinoma (TSCC) via transient receptor potential vanilloid 1 (TRPV1) receptor and the Calpain Pathway. (a, b) TRPV1 messenger RNA expression in head and neck squamous cell carcinoma based on sample types (a), tumor grade (b) in TCGA database. (c) Protein expression of TRPV1 in HOK, HN6, Cal27 and SCC9 cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the normalized control. (d) Annexin V-FITC/PI double staining showed that Ruthenium red (RR), a TRPV generalized antagonist, inhibits apoptosis induced by CAP and/or DDP in HN6 and Cal27 cells. (e) Capsazepine (CPZ), an antagonist of TRPV1 receptor, inhibits the pro-apoptotic effect induced by CAP and/or DDP in HN6 and Cal27 cells. (f) The protein expression of TRPV1 in HN6 cells that were transfected with short hairpin RNAs (shRNAs, sh1, sh2, and sh3). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the normalized control. (g, h) Human calpain enzyme-linked immunosorbent assay (ELISA) showed the calpain activity after pretreated with BAPTA-AM (10 μM), a well-known membrane permeable Ca2+ chelator (g), and in TRPV1 stable knockdown cell lines (sh1 and sh2) after CAP and/or DDP treatment (h). Data are presented as the Mean ± SD derived from biological triplicates. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001.